U.S. Markets closed

IntelliCell Biosciences Announces the Addition of Mr. Sam Khashman to Board of Directors

NEW YORK, NY--(Marketwired - Oct 18, 2013) - IntelliCell Biosciences, Inc. ( OTCQB : SVFC ), a regenerative medicine company utilizing adult autologous vascular fraction cells (SVFCs) derived from the blood vessels in lipoaspirate, announced today the addition of Mr. Sam Khashman to the company's Board of Directors.

During the past 20 years, Mr. Khashman has successfully directed the creation and launch of 14 products and 3 companies in the healthcare, financial, and manufacturing sector. He currently serves as the President and Chief Executive Officer of Technology Partners, Inc. DBA IMAGINE Software. Mr. Khashman founded the company and created the IMAGINE practice management system that is currently used in 48 States by more than 10,000 physicians. In addition to his involvement in numerous civic and charitable organizations, Mr. Khashman serves on the board of the National Chamber Foundation, the public policy think tank of the U.S. Chamber of Commerce in Washington D.C. A native of Germany, Khashman graduated from both the University of Lüneburg and the University of North Carolina.

"We are honored to have Mr. Sam Khashman join our Board of Directors and look forward to leveraging his tremendous knowledge of the medical field, most notably in healthcare reimbursements," stated Dr. Steven Victor, Chairman and Chief Executive Officer of IntelliCell Biosciences. "Management believes that under the new Obamacare Program the IntelliCell Cellular Therapy will become a reimbursable medical cost. Mr. Khashman's expertise and longstanding industry relationships will allow us to navigate both current and future health care programs, as we expand our roster of patients that will now be able to receive reimbursements for their cellular therapy treatments."

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. One of the revenue streams IntelliCell is pursuing is placing its labs into Hospitals and Ambulatory Surgical Centers. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.